Secutrelvir

DRUG2 trials

Sponsors

Shionogi

Conditions

COVID-19SARS-CoV-2

Phase 3

A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

RecruitingNCT07743580

ShionogiSARS-CoV-2

Start: 2026-09-14End: 2028-12-31Target: 2000Updated: 2026-09-17

Study of Secutrelvir in Participants With COVID-19

RecruitingNCT07746544

ShionogiCOVID-19

Start: 2026-08-05End: 2027-08-31Target: 1200Updated: 2026-09-02